CTOs on the Move

Fulcrum Therapeutics

www.fulcrumtx.com

 
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum`s proprietary product engine, FulcrumSeekâ„¢, identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Funding

Fulcrum Therapeutics raised $55M on 07/19/2016
Fulcrum Therapeutics raised $80M on 09/05/2018

Similar Companies

braunmedical

braunmedical is a Bethlehem, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EUSA Pharma Corporation

EUSA Pharma Corporation is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VGXI

VGXI is a Spring, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The THOR Group

The THOR Group is a Manhattan Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mind Medicine

MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.